Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243552 | 0.97 | LMNA (0.40) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL695544 | 0.94 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL555010 | 0.94 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| Methylamine SCHEMBL17749558 | 0.91 | FDPS (0.41) | LMNAFDPSCA2ALDH1A1 | |
| Tetramethylammonium Ion SCHEMBL238777 | 0.88 | LMNA (0.35) | LMNAFDPSCA2 | |
| SCHEMBL571123 | 0.85 | LMNA (0.36) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL27947422 | 0.84 | PGK1 (0.35) | LMNAFDPS | |
| SCHEMBL3817093 | 0.82 | LMNA (0.41) | LMNAFDPSCA2ALDH1A1 | |
| SCHEMBL21815536 | 0.80 | LMNA (0.33) | LMNAFDPS | |
| SCHEMBL21882618 | 0.80 | FDPS (0.38) | LMNAFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105367482-B | N acyl sulfonamides apoptosis accelerator | 阿斯利康(瑞典)有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| CN-105367482-A | N-acylsulfamide apoptosis accelerator | ASTRAZENECA AB | 2016-03-02 | — | — | CN | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| CN-103153954-B | N-acylsulfonamide apoptosis promoters | ASTRAZENECA AB (SE) | 2015-11-25 | — | — | CN | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153954-A | N-acylsulfonamide apoptosis promoters | ASTRAZENECA AB | 2013-06-12 | — | — | CN | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | LMNA 2184/4885FDPS 1169/4885CA2 420/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | LMNA 2184/4885FDPS 1169/4885CA2 420/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | LMNA 2184/4885FDPS 1169/4885CA2 420/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | LMNA 547/4885FDPS 1143/4885CA2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.